Literature DB >> 21577303

Which is the best choice for gastroesophageal disorders: Melatonin or proton pump inhibitors?

Joanna Dulce Favacho de Oliveira Torres1, Ricardo de Souza Pereira.   

Abstract

Melatonin is used in many countries to improve sleep disorders. Melatonin is a hormone produced by the pineal gland and enterochromaffin cells which control sleep and gastrointestinal motility. Low levels of melatonin lead to gastroesophageal reflux disease (GERD). Most of patients with GERD have a sleep disorder. So, low melatonin levels is the main cause of insomnia. Beyond this, it has an inhibitory action on gastric acid secretion and seems to control the lower esophageal sphincter. Proton pump inhibitors (PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available today. Omeprazole (one of the PPIs) and melatonin have similarities in their chemical structures. Therefore, we could consider omeprazole as a rough copy of melatonin. In this paper, we compare the advantages and disadvantages of the clinical use of melatonin and PPIs.

Entities:  

Keywords:  Gastritis; Gastroesophageal reflux disease; Melatonin; Omeprazole; Sleep disorder; Ulcers

Year:  2010        PMID: 21577303      PMCID: PMC3091156          DOI: 10.4292/wjgpt.v1.i5.102

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  21 in total

1.  Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole.

Authors:  Ricardo de Souza Pereira
Journal:  J Pineal Res       Date:  2006-10       Impact factor: 13.007

2.  Regression of an esophageal ulcer using a dietary supplement containing melatonin.

Authors:  Ricardo de Souza Pereira
Journal:  J Pineal Res       Date:  2006-05       Impact factor: 13.007

Review 3.  Systemic pharmacomodulation of transient lower esophageal sphincter relaxations.

Authors:  R H Holloway
Journal:  Am J Med       Date:  2001-12-03       Impact factor: 4.965

Review 4.  Melatonin as an organoprotector in the stomach and the pancreas.

Authors:  Jolanta Jaworek; Tomasz Brzozowski; Stanislaw Jan Konturek
Journal:  J Pineal Res       Date:  2005-03       Impact factor: 13.007

Review 5.  Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety.

Authors:  James C Ballenger; Jonathan R T Davidson; Yves Lecrubier; David J Nutt; Randall D Marshall; Charles B Nemeroff; Arieh Y Shalev; Rachel Yehuda
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

6.  Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux.

Authors:  Asgaut Viste; Kjell Øvrebø; Helga Maartmann-Moe; Helge Waldum
Journal:  Gastric Cancer       Date:  2004       Impact factor: 7.370

Review 7.  Melatonin in plants.

Authors:  Rosamaria Caniato; Raffaella Filippini; Anna Piovan; Lucia Puricelli; Anna Borsarini; Elsa M Cappelletti
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

Review 8.  Melatonin and serotonin effects on gastrointestinal motility.

Authors:  P J Thor; G Krolczyk; K Gil; D Zurowski; L Nowak
Journal:  J Physiol Pharmacol       Date:  2007-12       Impact factor: 3.011

9.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.

Authors:  Sandra Dial; Khalid Alrasadi; Chantal Manoukian; Allen Huang; Dick Menzies
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

10.  Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.

Authors:  B T Cooper; W Chapman; C S Neumann; J C Gearty
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

View more
  1 in total

1.  Does a melatonin supplement alter the course of gastro-esophageal reflux disease?

Authors:  Mariusz H Madalinski
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-12-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.